Zeo ScientifiX Appoints Dr. John D. Kisiday as Chief Science Officer

summarizeSummary

Zeo ScientifiX, Inc. appointed Dr. John D. Kisiday, Ph.D., a veteran in tissue engineering and regenerative medicine, as its new Chief Science Officer, effective January 23, 2026.

check_boxKey Events

• Appointment of Chief Science Officer

  Dr. John D. Kisiday, Ph.D., with almost 30 years of experience in tissue engineering and regenerative medicine, was appointed Chief Science Officer, effective January 23, 2026.

• Compensation Package Details

  Dr. Kisiday will receive an annual base salary of $175,000 and a grant of 50,000 shares of common stock, vesting over two years. He is also eligible for additional compensation for bringing commercially viable new products or business opportunities to the company.

• Strategic Alignment

  This key scientific hire follows the company's recent strategic partnership announcement on January 7, 2026, and aims to bolster its capabilities in product development and commercialization within the life sciences sector.

auto_awesomeAnalysis

This appointment significantly strengthens Zeo ScientifiX's scientific leadership, bringing nearly 30 years of experience in tissue engineering and regenerative medicine to the company. Dr. Kisiday's expertise is crucial for advancing the company's research initiatives and commercializing new therapies, aligning with recent strategic partnerships announced on January 7, 2026. His compensation package, including a substantial stock grant and potential for additional compensation for new product development, incentivizes growth and innovation in a key scientific role for this nano-cap life sciences company.